Following a major push by the industry’s heavyweights to simplify their businesses in recent years, Tanabe Pharma is | While ...
When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no FDA-approved treatment options. | When Vera Therapeutics in-licensed ...
Novartis is executing more layoffs at its U.S. headquarters in East Hanover, New Jersey, handing 322 employees pink slips.
As Bristol Myers Squibb attempts to convert two accelerated oncology nods for Krazati into traditional FDA approvals, the ...
Heidi, an “AI Care Partner” that helps clinicians save time and reduce burn out through an array of AI tools, is laying out a unique set of desirable "side effects" in a new brand campaign that puts a ...
Vertex has secured a label expansion through the FDA's Commis | Vertex Pharmaceuticals has gained a label expansion from the ...
The tables have turned for the U.S. biosimilars market. With more than a decade since the first FDA biosim approval, strong launches to biologic copies to AbbVie’s Humira, J&J’s Stelara and ...
Amgen has issued a voluntary recall for nearly 1 million bottles of the heart medication Corlanor (ivabradine) due to possible contamination. The nationwide recall was issued by the company on June 4 ...
Biopharma giants Eli Lilly and Regeneron and rapidly growing contract manufacturers Fujifilm and Cellares, are among the ...
Amgen has resisted that withdrawal push, prompting the FDA to double down in April with a formal proposal to pull the drug ...
Viridian Therapeutics has scored an FDA approval for Lumvoa to treat thyroid eye disease (TED), triggering competition with ...
Orca Bio has jumped into the commercial market with FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants. | Orca Bio has jumped into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results